Chronic GVHD: Intersecting Aspects in Systemic and Ocular Disease

摘要： 慢性眼部GVHD（oGVHD）已被认为是同种异体移植术后的重要并发症 造血干细胞移植（HSCT）是长期发病和死亡的主要原因 同种异体 HSCT 后。拟议的题为“慢性 GVHD：系统性交叉方面”的会议 和眼部疾病”将解决干眼和眼表疾病领域固有的难题 由于慢性眼部 GVHD - 传播信息和制定新的治疗方法存在困难 利益相关者在快速变化的学科（眼 GVHD 的科学和临床治疗）中的策略 来自多个不同的群体（临床医生、临床实习生和眼科、血液学、 肿瘤学和免疫学）。这次会议致力于眼科医生和眼科医生之间的交叉 从事慢性 GVHD 和干眼/眼表疾病领域工作的血液学家/肿瘤学家。由 汇集了来自不同学科的临床医生和科学家，包括国家认可的专家， 会议将降低沟通障碍，促进跨学科研究和教育 促进改善慢性眼 GVHD 患者的治疗。 我们于 2016 年 10 月 22 日在伊利诺伊大学举行了第二次慢性 GVHD 会议 芝加哥 (UIC) 医学院 (COM) 学习中心。我们建议模拟未来的会议（2017-2022） 关于 2016 年会议的成功举办。本次赠款申请的总体目标是要求 支持年度会议在未来5年期间实现三个目标的各个方面。刺激 临床和转化跨学科合作以及新的研究领域，会议将带来 与国家认可的专家（血液学家/肿瘤学家和眼科医生）一起传播新的 慢性全身性和眼部 GVHD 领域的发现（目标 1）。促进机构间和 研究、临床实践和教育方面的跨学科机会，会议将汇集五位 骨髓移植计划与芝加哥地区6个眼科科室洽谈 他们在 HSCT 和慢性 GVHD 管理方面的差异以及障碍/机会 临床和研究合作（目标 2）。加强初级和高级科学家之间的合作 血液学/肿瘤学和眼科领域，将颁发20个旅行奖励，以增加 追求研究职业发展和早期基础科学的临床医生的参与 眼表疾病和 GVHD 领域的研究人员（目标 3）。将优先考虑女性， 少数种族/族裔和残疾人。慢性 GVHD 会议计划于 符合继续医疗认证委员会的基本领域和政策 教育（ACCME）由伊利诺伊大学芝加哥分校（UIC）赞助。范围和格式 这次会议很独特，与关于慢性病的小型指导课程或共识会议有很大不同。 过去 3 年举行过眼部 GVHD。

Abstract: Chronic ocular GVHD (oGVHD) has been recognized as an important complication after allogeneic hematopoietic stem cell transplantation (HSCT) and is the leading cause of long-term morbidity and mortality following allogeneic HSCT. The proposed meeting entitled “Chronic GVHD: Intersecting aspects in systemic and ocular disease” will address a difficulty that is intrinsic in the area of dry eye and ocular surface disease due to chronic ocular GVHD - the difficulty in disseminating information and developing new management strategies in a fast-changing discipline (science and clinical treatment of ocular GVHD) where the stakeholders come from multiple disparate pools (clinician, clinical trainees and researchers in ophthalmology, hematology, oncology and immunology). This meeting is devoted to the intersection between ophthalmologist and hematologists/oncologists working in the areas of chronic GVHD and dry eye/ocular surface disease. By bringing together clinicians and scientists from different disciplines, including nationally recognized experts, this meeting will lower the communication barrier and promote interdisciplinary research and education and facilitate improvements in the management of patients with chronic ocular GVHD. We conducted the second Chronic GVHD Meeting on October 22, 2016 at the University of Illinois at Chicago (UIC) College of Medicine (COM) learning center. We propose to model future meetings (2017-2022) on the successful format of the 2016 meeting. The overall objective of this grant application is to request support for aspects of the annual meeting for the next 5-year period for achieving three aims. To stimulate clinical and translational interdisciplinary collaborations and new lines of research, the meeting will bring together nationally recognized experts (hematologist/oncologists and ophthalmologists) for disseminating new findings in the area of chronic systemic and ocular GVHD (Aim 1). To stimulate inter-institutional and interdisciplinary opportunities in research, clinical practice and education, the meeting will bring together five bone marrow transplant programs and six ophthalmology departments in the Chicago area to discuss differences in their approach to HSCT and chronic GVHD management and impediments/opportunities in clinical and research collaborations (Aim 2). To increase collaboration amongst junior and senior scientists in the fields of hematology/oncology and ophthalmology, 20 travel awards will be made to increase the participation of clinicians who are pursuing research career development and early stage basic science researchers in the areas of ocular surface disease and GVHD (Aim 3). Preference will be given to women, racial/ethnic minorities and persons with disabilities. The Chronic GVHD meeting has been planned in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) under the sponsorship of University of Illinois at Chicago (UIC). The scope and format of the meeting is unique and very different from the small instruction courses or consensus meetings on chronic ocular GVHD held in the past 3 years.